secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001437749-25-024480
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q2 BRIUMVI revenue $138.8M (+91% YoY); raises FY guidance to $570-575M
--------------------------------------------------------------------------------

- Q2 2025 total revenue $141.1M; BRIUMVI U.S. net sales $138.8M, up 91% YoY vs $72.6M.
- Net income $28.2M in Q2 2025 vs $6.9M in Q2 2024; cash and securities $278.9M.
- Raises FY 2025 BRIUMVI U.S. net revenue guidance to $570-575M (prior $560M); total global revenue target ~$585M.
- R&D expense $31.8M (up from $17.6M) driven by subcutaneous development; SG&A $55.6M (up from $38.8M) for commercialization.
- Pipeline: Phase 3 ENHANCE trial for consolidated IV dosing ongoing; Phase 1 azer-cel in autoimmune diseases first patient dosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/0001437749-25-024480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/tgtx20250724_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-024480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer